Component

Ezetimibe

Ezetimibe. Species, exposure and limitations are retained in each linked claim.

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Ezetimibe reduced lutein accumulation by up to 40% in Caco-2 monolayers.

    Ezetimibe → Intestinal epithelial lutein uptake source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/lutein-research/22579005.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1dd51af5fd10e865810b3fa2fdab5ed4f6613212a3cd418a009554ae601c076b", "start_char": 0, "end_char": 1895, "text_sha256": "1dd51af5fd10e865810b3fa2fdab5ed4f6613212a3cd418a009554ae601c076b"}
    experimental_model
    Transporter-inhibitor uptake/permeability experiment
    exposure
    Ezetimibe, BLT1 and ATP-depletion reagents
    limitations
    Pharmacological evidence supports involvement, not an exclusive transporter or proven human clinical interaction.
    nutrient_topic
    Lutein research collection; topical membership is not evidence of a direct dietary effect. · Lutein
    organism
    Human Caco-2 cells
    plain_language
    The medicine reduced cellular uptake in this experiment.
    primary_references
    [lutein-p22579005] Involvement of cholesterol membrane transporter Niemann-Pick C1-like 1 in the intestinal absorption of lutein. (2012). https://pubmed.ncbi.nlm.nih.gov/22579005/ DOI: 10.18433/j38k56
    tissue_or_cell_type
    Intestinal epithelial model

    Lutein: metabolism, signaling and nutrient connections (2026-09-17) · lines 528–539

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Transporter-inhibitor uptake/permeability experiment · source_derived_draft · unverified_draft

    ### lutein-ezetimibe-intestine Ezetimibe reduced lutein accumulation by up to 40% in Caco-2 monolayers. Condition category: normal nutrient_topic: Lutein research collection; topical membership is not evidence of a direct dietary effect. plain_language: The medicine reduced cellular uptake in this experiment. organism: Human Caco-2 cells tissue_or_cell_type: Intestinal epithelial model experimental_model: Transporter-inhibitor uptake/permeability experiment limitations: Pharmacological evidence supports involvement, not an exclusive transporter or proven human clinical interaction. exposure: Ezetimibe, BLT1 and ATP-depletion reagents evidence_span: {"source_cache": "artifacts/lutein-research/22579005.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "1dd51af5fd10e865810b3fa2fdab5ed4f6613212a3cd418a009554ae601c076b", "start_char": 0, "end_char": 1895, "text_sha256": "1dd51af5fd10e865810b3fa2fdab5ed4f6613212a3cd418a009554ae601c076b"} [lutein-p22579005] Involvement of cholesterol membrane transporter Niemann-Pick C1-like 1 in the intestinal absorption of lutein. (2012). https://pubmed.ncbi.nlm.nih.gov/22579005/ DOI: 10.18433/j38k56
    Complete structured claim and evidence

  2. Ezetimibe reduced free-zeaxanthin uptake in the Caco-2 inhibitor experiment.

    Ezetimibe → Zeaxanthin uptake in intestinal epithelial models source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/zeaxanthin-research/42123990.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c0b42011e7f16c3fe60d599d489d01e4b3098db9ad04856d26aca10008e995f4", "start_char": 0, "end_char": 1803, "text_sha256": "c0b42011e7f16c3fe60d599d489d01e4b3098db9ad04856d26aca10008e995f4"}
    experimental_model
    Micelle uptake, transporter inhibition and protein-expression assays
    exposure
    Free and dipalmitate xanthophyll micelles; BLT-1 and ezetimibe
    limitations
    Inhibitors support pathway involvement rather than exclusivity. Protein-expression changes do not prove efflux; a cell model cannot establish clinical drug spacing.
    nutrient_topic
    Zeaxanthin research collection; topical membership is not evidence of a direct dietary effect. · Dietary (3R,3-prime-R)-zeaxanthin
    organism
    Human Caco-2 monolayers
    plain_language
    The drug reduced uptake in cells; clinical importance remains unknown.
    primary_references
    [zeaxanthin-p42123990] Mechanisms of Cell Uptake and Transport of Xanthophylls in the Caco-2 Cell Model. (2026). https://pubmed.ncbi.nlm.nih.gov/42123990/ DOI: 10.3390/nu18091389
    tissue_or_cell_type
    Intestinal epithelial model

    Zeaxanthin: metabolism, signaling and nutrient connections (2026-09-17) · lines 743–754

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Micelle uptake, transporter inhibition and protein-expression assays · source_derived_draft · unverified_draft

    ### zeaxanthin-ezetimibe-uptake Ezetimibe reduced free-zeaxanthin uptake in the Caco-2 inhibitor experiment. Condition category: normal nutrient_topic: Zeaxanthin research collection; topical membership is not evidence of a direct dietary effect. plain_language: The drug reduced uptake in cells; clinical importance remains unknown. organism: Human Caco-2 monolayers tissue_or_cell_type: Intestinal epithelial model experimental_model: Micelle uptake, transporter inhibition and protein-expression assays limitations: Inhibitors support pathway involvement rather than exclusivity. Protein-expression changes do not prove efflux; a cell model cannot establish clinical drug spacing. exposure: Free and dipalmitate xanthophyll micelles; BLT-1 and ezetimibe evidence_span: {"source_cache": "artifacts/zeaxanthin-research/42123990.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "c0b42011e7f16c3fe60d599d489d01e4b3098db9ad04856d26aca10008e995f4", "start_char": 0, "end_char": 1803, "text_sha256": "c0b42011e7f16c3fe60d599d489d01e4b3098db9ad04856d26aca10008e995f4"} [zeaxanthin-p42123990] Mechanisms of Cell Uptake and Transport of Xanthophylls in the Caco-2 Cell Model. (2026). https://pubmed.ncbi.nlm.nih.gov/42123990/ DOI: 10.3390/nu18091389
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Simvastatin, alone or with ezetimibe, lowered plasma CoQ; CoQ change correlated with LDL-cholesterol change and the CoQ-to-LDL ratio increased.

    Simvastatin → Plasma coenzyme Q10 concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/coq10-research/16872244.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "65abd11b5f58ce1125f554d52ed5203575d7a3ba0d20b789abce16148f3b5e27", "start_char": 0, "end_char": 2245, "text_sha256": "65abd11b5f58ce1125f554d52ed5203575d7a3ba0d20b789abce16148f3b5e27"}
    experimental_model
    Randomized three-arm parallel study
    exposure
    Simvastatin 40 mg/day, ezetimibe 10 mg/day or both for 14 days
    limitations
    Plasma measurements and correlation; neither tissue CoQ nor mitochondrial dysfunction was demonstrated.
    nutrient_topic
    Coenzyme Q10 research collection; topical membership is not evidence of a direct dietary effect. · Coenzyme Q10 / CoQ10 redox system
    organism
    72 healthy men
    plain_language
    The blood concentration also depends on the particles carrying CoQ.
    primary_references
    [coq10-p16872244] Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. (2006). https://pubmed.ncbi.nlm.nih.gov/16872244/ DOI: 10.2165/00002018-200629080-00007
    tissue_or_cell_type
    Plasma CoQ and lipoprotein concentrations

    Coenzyme Q10: biosynthesis, electron transfer, antioxidant recycling and nutrient interactions (2026-09-17) · lines 931–942

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomized three-arm parallel study · source_derived_draft · unverified_draft

    ### coq10-statin-plasma-carriers Simvastatin, alone or with ezetimibe, lowered plasma CoQ; CoQ change correlated with LDL-cholesterol change and the CoQ-to-LDL ratio increased. Condition category: normal nutrient_topic: Coenzyme Q10 research collection; topical membership is not evidence of a direct dietary effect. plain_language: The blood concentration also depends on the particles carrying CoQ. organism: 72 healthy men tissue_or_cell_type: Plasma CoQ and lipoprotein concentrations experimental_model: Randomized three-arm parallel study limitations: Plasma measurements and correlation; neither tissue CoQ nor mitochondrial dysfunction was demonstrated. exposure: Simvastatin 40 mg/day, ezetimibe 10 mg/day or both for 14 days evidence_span: {"source_cache": "artifacts/coq10-research/16872244.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "65abd11b5f58ce1125f554d52ed5203575d7a3ba0d20b789abce16148f3b5e27", "start_char": 0, "end_char": 2245, "text_sha256": "65abd11b5f58ce1125f554d52ed5203575d7a3ba0d20b789abce16148f3b5e27"} [coq10-p16872244] Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. (2006). https://pubmed.ncbi.nlm.nih.gov/16872244/ DOI: 10.2165/00002018-200629080-00007
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards